Form 4: Agios Pharmaceuticals CMO Sarah Gheuens Reports Routine Stock Transactions

Agios Pharmaceuticals' Chief Medical Officer, Sarah Gheuens, reported the acquisition of common stock through restricted stock unit vesting and a subsequent sale to cover tax obligations, as part of a pre-arranged 10b5-1 plan.

Summary

• Chief Medical Officer Sarah Gheuens acquired 8,374 shares of Agios Pharmaceuticals common stock on July 1, 2025, through the vesting of restricted stock units.
• Concurrently, Gheuens disposed of 4,091 shares of common stock at a price of $34.17 per share on July 1, 2025.
• The sale of 4,091 shares was executed to satisfy tax withholding obligations related to the vesting of her restricted stock units.
• This transaction was conducted under a Rule 10b5-1 pre-arranged trading plan, established on July 1, 2023.
• Following these transactions, Sarah Gheuens beneficially owns 61,271 shares of common stock and 8,375 restricted stock units.

Sentiment

Score: 5

Explanation: The sentiment is neutral. This is a routine insider transaction related to equity compensation and tax obligations, executed under a pre-arranged plan. It does not indicate any significant positive or negative operational or financial developments for the company.

Positives

• The acquisition of shares through restricted stock unit vesting indicates continued equity incentive alignment between management and shareholders.
• The transaction was executed under a Rule 10b5-1 plan, demonstrating a pre-planned and transparent approach to insider stock sales.

Negatives

• A reduction in direct common stock ownership by a key executive, even if for tax purposes, slightly decreases their direct stake.

Future Outlook

The remaining restricted stock units are scheduled to vest in two additional equal annual installments following the initial vesting on July 1, 2024.

Management Comments

• Shares were sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted share units.
• This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act.

Industry Context

This Form 4 filing details a routine insider transaction, common across all industries, where executives manage their equity compensation through pre-arranged plans to cover tax liabilities upon vesting of restricted stock units. It does not provide specific insights into broader pharmaceutical industry trends or competitive dynamics.

Stakeholder Impact

• Shareholders: A minor, routine reduction in direct insider ownership due to tax-related sales, generally not indicative of a change in management's confidence.
• Employees: The vesting of RSUs is a standard part of executive compensation, aligning executive interests with company performance.

Next Steps

• Future vesting of remaining restricted stock units in two equal annual installments.

Key Dates

Keywords

Agios Pharmaceuticals, AGIO, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Stock Sale, Tax Withholding, 10b5-1 Plan, Sarah Gheuens, Chief Medical Officer